Clinical Scorecard: FARETINA Study Confirms Faricimab Durability
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Faricimab (Vabysmo) treatment for wet AMD |
| Target Population | Patients with treatment-naïve and previously treated neovascular AMD |
| Care Setting | Real-world clinical setting using the IRIS Registry |
Key Highlights
- Stable vision maintained over 2 years in both treatment-naïve and previously treated groups
- Anatomic improvement observed in both groups
- Reduction in treatment burden with fewer injections over time
- Low rates of endophthalmitis (<0.1%) and intraocular inflammation (<0.5%)
- Diverse patient population beyond typical clinical trial participants
Guideline-Based Recommendations
Diagnosis
- Diagnosis of neovascular AMD based on clinical and anatomic assessments
Management
- Initiation of faricimab treatment for eligible patients with neovascular AMD
Monitoring & Follow-up
- Regular follow-up to assess vision and anatomic outcomes during treatment
Risks
- Monitor for low rates of endophthalmitis and intraocular inflammation
Patient & Prescribing Data
Approximately 6,500 treatment-naïve eyes and 40,000 previously treated eyes
Average of 4 to 5 injections required in the first year, with extended intervals in the second year
Clinical Best Practices
- Utilize real-world data to inform treatment decisions
- Consider patient history of previous treatments when initiating faricimab
- Monitor for safety and efficacy outcomes in diverse patient populations
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.